📊 EXEL Key Takeaways
Is Exelixis, Inc.. (EXEL) a Good Investment?
Exelixis demonstrates fortress-like financial strength with zero debt, exceptional profitability (41.1% operating margin), and outstanding free cash flow generation ($250.3M FCF at 41% margin), creating a low-risk, high-return cash-generating machine. However, modest revenue growth of 7% YoY and moderate ROE of 10.9% suggest the company may be leveraging operational efficiency and share buybacks to drive the impressive 58% EPS growth rather than underlying business expansion, warranting cautious optimism on fundamentals.
Exelixis shows strong fundamental quality through high operating and net profitability, very strong free cash flow generation, and a debt-free balance sheet with ample liquidity. Revenue growth is moderate rather than explosive, but earnings growth materially outpaced sales, indicating improved operating leverage and strong business efficiency; however, one reported margin figure appears internally inconsistent, which tempers conviction.
Why Buy Exelixis, Inc.. Stock? EXEL Key Strengths
- Exceptional operating margin of 41.1% and net margin of 34.5% indicating superior profitability and operational efficiency
- Zero long-term debt with fortress balance sheet (Debt/Equity 0.00x) and excellent liquidity (Current Ratio 3.26x, Quick Ratio 3.19x)
- Outstanding free cash flow generation of $250.3M with 41% FCF margin, converting nearly all operating cash to unlevered cash returns
- Strong EPS growth of 58% YoY, demonstrating effective capital allocation and earnings expansion
- Minimal capital intensity ($1.5M capex) characteristic of profitable pharma/biotech with established products
- Strong earnings growth with net income up 50.1% and diluted EPS up 58.0% year over year
- Excellent financial health with $482.49M in cash, no long-term debt, and strong liquidity ratios above 3.5x
- High cash conversion with $884.27M in operating cash flow and $875.84M in free cash flow, supporting resilience and capital flexibility
EXEL Stock Risks: Exelixis, Inc.. Investment Risks
- Modest top-line revenue growth of 7% YoY raises concerns about product pipeline maturity and limited organic expansion in biotech sector
- Moderate return metrics (ROE 10.9%, ROA 8.1%) suggest capital may not be generating exceptional returns despite strong margins
- Inherent biotech sector risks including patent expirations, clinical trial failures, regulatory changes, and competitive product launches
- EPS growth significantly outpacing revenue growth (58% vs 7%) suggests reliance on operational leverage or share buybacks rather than organic business growth
- Heavy dependence on existing product portfolio with unclear visibility into new product commercial success
- Revenue growth of 7.0% is solid but not especially high, so future returns depend on sustaining margin strength
- Profitability may be concentrated in a limited set of products or royalty streams, which can increase business concentration risk
- Reported gross profit and gross margin appear inconsistent with operating income and operating margin, creating some uncertainty around data quality
Key Metrics to Watch
- Quarterly revenue growth trajectory—critical to confirm whether 7% YoY represents stabilization or continued deceleration
- Free cash flow sustainability and capital allocation priorities (dividends, buybacks, acquisitions, R&D investment)
- Product pipeline advancement and clinical trial outcomes for new drug candidates to assess future organic growth potential
- Revenue growth versus net income growth to confirm earnings quality and durability
- Operating margin and free cash flow margin consistency, especially given the apparent gross margin data anomaly
Exelixis, Inc.. (EXEL) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The 41.0% free cash flow margin provides substantial flexibility for dividends, buybacks, and strategic investments. Strong liquidity with a 3.26x current ratio provides a solid financial cushion.
EXEL Profit Margin, ROE & Profitability Analysis
EXEL vs Healthcare Sector: How Exelixis, Inc.. Compares
How Exelixis, Inc.. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Exelixis, Inc.. Stock Overvalued? EXEL Valuation Analysis 2026
Based on fundamental analysis, Exelixis, Inc.. appears fundamentally strong relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Exelixis, Inc.. Balance Sheet: EXEL Debt, Cash & Liquidity
EXEL Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Exelixis, Inc..'s revenue has grown significantly by 62% over the 5-year period, indicating strong business expansion. The most recent EPS of $0.65 reflects profitable operations.
EXEL Revenue Growth, EPS Growth & YoY Performance
EXEL Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $555.4M | $159.6M | $0.55 |
| Q3 2025 | $539.5M | $118.0M | $0.40 |
| Q2 2025 | $568.3M | $184.8M | $0.65 |
| Q1 2025 | $425.2M | $37.3M | $0.12 |
| Q3 2024 | $471.9M | $1.0M | $0.00 |
| Q2 2024 | $469.8M | $81.2M | $0.25 |
| Q1 2024 | $408.8M | $37.3M | $0.12 |
| Q3 2023 | $411.7M | $1.0M | $0.00 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Exelixis, Inc.. Dividends, Buybacks & Capital Allocation
EXEL SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Exelixis, Inc.. (CIK: 0000939767)
📋 Recent SEC Filings
❓ Frequently Asked Questions about EXEL
What is the AI rating for EXEL?
Exelixis, Inc.. (EXEL) has a Combined AI Rating of BUY from Claude (BUY) and ChatGPT (BUY) with 75% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are EXEL's key strengths?
Claude: Exceptional operating margin of 41.1% and net margin of 34.5% indicating superior profitability and operational efficiency. Zero long-term debt with fortress balance sheet (Debt/Equity 0.00x) and excellent liquidity (Current Ratio 3.26x, Quick Ratio 3.19x). ChatGPT: Strong earnings growth with net income up 50.1% and diluted EPS up 58.0% year over year. Excellent financial health with $482.49M in cash, no long-term debt, and strong liquidity ratios above 3.5x.
What are the risks of investing in EXEL?
Claude: Modest top-line revenue growth of 7% YoY raises concerns about product pipeline maturity and limited organic expansion in biotech sector. Moderate return metrics (ROE 10.9%, ROA 8.1%) suggest capital may not be generating exceptional returns despite strong margins. ChatGPT: Revenue growth of 7.0% is solid but not especially high, so future returns depend on sustaining margin strength. Profitability may be concentrated in a limited set of products or royalty streams, which can increase business concentration risk.
What is EXEL's revenue and growth?
Exelixis, Inc.. reported revenue of $610.8M.
Does EXEL pay dividends?
Exelixis, Inc.. does not currently pay dividends.
Where can I find EXEL SEC filings?
Official SEC filings for Exelixis, Inc.. (CIK: 0000939767) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is EXEL's EPS?
Exelixis, Inc.. has a diluted EPS of $0.79.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is EXEL a good stock to buy right now?
Based on our AI fundamental analysis in May 2026, Exelixis, Inc.. has a BUY rating with 75% confidence. The AI analysis suggests favorable fundamentals based on SEC filings. This is not investment advice.
Is EXEL stock overvalued or undervalued?
Valuation metrics for EXEL: ROE of 10.9% (sector avg: 15%), net margin of 34.5% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy EXEL stock in 2026?
Our dual AI analysis gives Exelixis, Inc.. a combined BUY rating for 2026. Revenue is data pending, with profitability above sector average. Always conduct your own research.
What is EXEL's free cash flow?
Exelixis, Inc..'s operating cash flow is $251.8M, with capital expenditures of $1.5M. FCF margin is 41.0%.
How does EXEL compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 34.5% (avg: 12%), ROE 10.9% (avg: 15%), current ratio 3.26 (avg: 2).